Role of Interleukin-28B Genetic Polymorphisms in Korean Patients with Hepatitis C Virus Infection

被引:7
作者
Kil, Ho [1 ]
Jeong, Sook-Hyang [1 ]
Kim, Jin-Wook [1 ]
Byoun, Young Sang [1 ]
Min, Bo Young [1 ]
Woo, Byung-Hyun [1 ]
Lee, Youn Jae [2 ]
Kim, Young Seok [3 ]
机构
[1] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Internal Med, Songnam 463707, South Korea
[2] Inje Univ, Busan Baik Hosp, Coll Med, Dept Internal Med, Pusan, South Korea
[3] Soonchunhyang Univ, Bucheon Hosp, Coll Med, Dept Internal Med, Puchon, South Korea
关键词
Hepatitis C; Interleukin-28B; Recovery; Treatment; Korea; SPONTANEOUS CLEARANCE; IL28B; GENOTYPE; ASSOCIATION; THERAPY; SAFETY;
D O I
10.5009/gnl.2014.8.1.70
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: This study investigated the role of single nucleotide polymorphisms (SNPs) near the interleukin-28B (IL28B) gene with respect to clinical outcomes and the antiviral response in hepatitis C virus (HCV) infection to suggest the practical utility of 1288 genotyping in Korea. Methods: Two SNPs near IL28B, rs12979860 and rs8099917, were analyzed using an allelic discrimination assay in a total of 454 individuals, including 147 health-check examinees and 307 patients with HCV infection. Results: The CC genotype frequency was significantly higher in the spontaneous recovery group than in the chronic infection group and was higher in the chronic hepatitis group than in the liver cirrhosis or hepatocellular carcinoma group, suggesting its favorable role in the clinical outcome. Multivariate analysis revealed that the rs12979860 CC genotype was an independent predictor of sustained virologic response (SVR) in genotype 1 HCV infection. During the currently used response-guided therapy, IL28B genotyping was most helpful for the patients who exhibit early virologic responses without rapid virologic responses, as those patients exhibiting the non-CC type did not achieve SVR, although they represented approximately one-third of the total patients. Conclusions: The IL28B SNP is an independent predictor of SVR. Our results may be helpful if the findings are carefully applied to select patients in Korea.
引用
收藏
页码:70 / 78
页数:9
相关论文
共 28 条
  • [1] Antitumor activity of Type I and Type III interferons in BNL hepatoma model
    Abushahba, Walid
    Balan, Murugabaskar
    Castaneda, Ismael
    Yuan, Yao
    Reuhl, Kenneth
    Raveche, Elizabeth
    de la Torre, Andrew
    Lasfar, Ahmed
    Kotenko, Sergei V.
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2010, 59 (07) : 1059 - 1071
  • [2] Management of Hepatocellular Carcinoma: An Update
    Bruix, Jordi
    Sherman, Morris
    [J]. HEPATOLOGY, 2011, 53 (03) : 1020 - 1022
  • [3] Craxì A, 2011, J HEPATOL, V55, P245, DOI 10.1016/j.jhep.2011.02.023
  • [4] IL-28B rs12979860 C/T allele distribution in patients with liver cirrhosis: Role in the course of chronic viral hepatitis and the development of HCC
    Fabris, Carlo
    Falleti, Edmondo
    Cussigh, Annarosa
    Bitetto, Davide
    Fontanini, Elisabetta
    Bignulin, Sara
    Cmet, Sara
    Fornasiere, Ezio
    Fumolo, Elisa
    Fangazio, Stefano
    Cerutti, Andrea
    Minisini, Rosalba
    Pirisi, Mario
    Toniutto, Pierluigi
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 (04) : 716 - 722
  • [5] Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
    Ge, Dongliang
    Fellay, Jacques
    Thompson, Alexander J.
    Simon, Jason S.
    Shianna, Kevin V.
    Urban, Thomas J.
    Heinzen, Erin L.
    Qiu, Ping
    Bertelsen, Arthur H.
    Muir, Andrew J.
    Sulkowski, Mark
    McHutchison, John G.
    Goldstein, David B.
    [J]. NATURE, 2009, 461 (7262) : 399 - 401
  • [6] An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
    Ghany, Marc G.
    Nelson, David R.
    Strader, Doris B.
    Thomas, David L.
    Seeff, Leonard B.
    [J]. HEPATOLOGY, 2011, 54 (04) : 1433 - 1444
  • [7] Potential Role for Interleukin-28B Genotype in Treatment Decision-Making in Recent Hepatitis C Virus Infection
    Grebely, Jason
    Petoumenos, Kathy
    Hellard, Margaret
    Matthews, Gail V.
    Suppiah, Vijayaprakash
    Applegate, Tanya
    Yeung, Barbara
    Marks, Phillipa
    Rawlinson, William
    Lloyd, Andrew R.
    Booth, David
    Kaldor, John M.
    George, Jacob
    Dore, Gregory J.
    [J]. HEPATOLOGY, 2010, 52 (04) : 1216 - 1224
  • [8] IL28B genetic polymorphism testing in the era of direct acting antivirals therapy for chronic hepatitis C: ten years too late?
    Jensen, Donald M.
    Pol, Stanislas
    [J]. LIVER INTERNATIONAL, 2012, 32 : 74 - 78
  • [9] Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b
    Kawaoka, Tomokazu
    Hayes, C. Nelson
    Ohishi, Waka
    Ochi, Hidenori
    Maekawa, Toshiro
    Abe, Hiromi
    Tsuge, Masataka
    Mitsui, Fukiko
    Hiraga, Nobuhiko
    Imamura, Michio
    Takahashi, Shoichi
    Kubo, Michaki
    Tsunoda, Tatsuhiko
    Nakamura, Yusuke
    Kumada, Hiromitsu
    Chayama, Kazuaki
    [J]. JOURNAL OF HEPATOLOGY, 2011, 54 (03) : 408 - 414
  • [10] Acute Hepatitis C in Korea: Different Modes of Infection, High Rate of Spontaneous Recovery, and Low Rate of Seroconversion
    Kim, Jong Yeop
    Won, Ji Eon
    Jeong, Sook-Hyang
    Park, Sang Jong
    Hwang, Seong Gyu
    Kang, Sook-Kyoung
    Bae, Si Hyun
    Kim, Young Seok
    Lee, Han Chu
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2011, 83 (07) : 1195 - 1202